Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Hims & Hers vs PlexusDx

Hims & Hers
Graded #36

Higher grade

vs+13.299999999999997
PlexusDx
Graded #158

Lower grade

The verdict

Hims & Hers takes it — 81/100 to 67.7/100.

Hims & Hers grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Mass-market app-first program with nationwide reach and consumer-grade polish.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueHims & Hers +8
82
74
Dose & formulationHims & Hers +14
78
64
Clinical oversightHims & Hers +8
82
74
Labs & monitoringHims & Hers +28
80
52
FulfillmentHims & Hers +6
84
78
Contract termsHims & Hers +25
80
55
Hims & Hers · left barPlexusDx · right bar

The numbers

MetricHims & HersPlexusDx
WeighScore81/10067.7/100
GradeB−C
Scorecard rank#36#158
Semaglutide$199/mo$149/mo (starting dose, compounded)
TirzepatideNot disclosed$249/mo (starting dose, compounded)
CoverageAll 50 statesAll 50 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
Hims & Hers

Graded #36 · B−

Strengths

  • Nationwide
  • Polished app
  • Strong brand trust

Where it loses points

  • Tirzepatide pricing inconsistently disclosed
  • Industry-wide compounding scrutiny
PlexusDx

Graded #158 · C

Strengths

  • Licensed providers available in all 50 states
  • Range of options including low-cost microdose GLP-1 from $129/mo
  • Optional Precision Peptide genetic panel adds a personalization angle
  • Independent clinician review via state-licensed telehealth platform
  • Compounded medications from state-licensed pharmacies

Where it loses points

  • Compounded medications only; no FDA-approved brand options
  • Specific compounding pharmacies not named
  • Genetic-panel upsell may not add clinical value for everyone
  • Tirzepatide pricing from $249/mo is higher than budget rivals
  • No insurance accepted

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard